The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
An article from
Emerging biotech
The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
Published June 8, 2026
Courtesy of Johnson & Johnson
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a…
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly…
Adquirida está desenvolvendo uma plataforma proprietária de conjugados anticorpo-degradador voltada para cânceres impulsionados…
Η πλατφόρμα Firelink της Firefly χρησιμοποιεί αντισώματα για να απελευθερώσει ένα φάρμακο που αποικοδομεί πρωτεΐνες απευθείας στα…
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
